Boston Scientific Corporation’s Q4 2024 Net Sales Surge by 22.4%, Exceeding Expectations

In the fourth quarter of 2024, Boston Scientific Corporation (NYSE: BSX) reported remarkable financial outcomes, showcasing significant growth across various metrics. The company achieved net sales of $4.561 billion, marking a 22.4% increase on a reported basis compared to the previous year. This growth was even more pronounced on an operational basis, reaching 23.1%, and on an organic basis, at 19.5%.

Additionally, Boston Scientific reported a GAAP net income attributable to common stockholders of $566 million, translating to $0.38 per share, compared to $504 million or $0.34 per share in the same period last year. The adjusted earnings per share (EPS) stood at $0.70, a significant improvement from $0.55 a year ago.

Boston Scientific Reports Better than Expected Results with $0.70 Adj. EPS

The company’s MedSurg segment reported net sales growth of 12.4% on a reported basis, with operational growth at 13.0% and organic growth at 7.0%. The Cardiovascular segment demonstrated even more robust growth, with a reported increase of 28.8%, operational growth of 29.5%, and organic growth of 27.4%. Regionally, the United States led the way with a 30.7% increase in both reported and operational sales. Europe, the Middle East, and Africa (EMEA) saw a 10.8% increase in reported sales, while the Asia-Pacific region experienced an 11.1% uptick. Latin America and Canada (LACA) reported a modest 4.6% increase, while emerging markets saw a 12.4% rise in reported sales.

Boston Scientific’s fourth-quarter performance exceeded market expectations in several key areas. The company reported adjusted EPS of $0.70, surpassing the anticipated range of $0.64 to $0.66.

This achievement demonstrates the company’s ability to outperform its projected earnings, driven by strong sales growth and operational efficiency. The company’s net sales of $4.561 billion also exceeded the expected revenue of $4.41 billion, highlighting its robust market presence and successful execution of strategic initiatives.

Despite this strong performance, the GAAP net income per share of $0.38 fell short of the company’s guidance range of $0.41 to $0.43. This discrepancy can be attributed to various factors, including amortization expenses, acquisition-related charges, and restructuring costs, which impacted the GAAP earnings.

Join our Telegram group and never miss a breaking digital asset story.

BSX Estimates GAAP EPS Between $1.86 and $1.93 for Full Year 2025

Boston Scientific has provided optimistic guidance for both the first quarter and the full year of 2025. The company estimates net sales growth for the full year to be in the range of 12.5% to 14.5% on a reported basis and 10% to 12% on an organic basis. For the first quarter of 2025, the company anticipates net sales growth of 17% to 19% on a reported basis and 14% to 16% on an organic basis. These projections reflect the company’s confidence in its ongoing growth initiatives and market strategy.

In terms of earnings, Boston Scientific estimates GAAP EPS for the full year 2025 to range between $1.86 and $1.93, with adjusted EPS projected between $2.80 and $2.87. For the first quarter, the company expects GAAP EPS to range from $0.43 to $0.45, while adjusted EPS is anticipated to be between $0.66 and $0.68. This guidance indicates the company’s focus on maintaining strong financial performance while navigating potential challenges in the market.

Boston Scientific’s strategic initiatives and recent developments have positioned the company for continued growth and innovation. The successful launch of the FARAPULSE™ Pulsed Field Ablation System and the positive clinical trial results for the WATCHMAN FLX™ Left Atrial Appendage Closure Device demonstrate the company’s commitment to advancing medical technology and improving patient outcomes. Additionally, the acquisition of companies like Axonics, Inc. and Cortex, Inc. highlights Boston Scientific’s strategy to expand its product portfolio and enhance its market presence.

Disclaimer: The author does not hold or have a position in any securities discussed in the article. All stock prices were quoted at the time of writing.